INmune Bio Inc (INMB)
7.68
-0.60
(-7.25%)
USD |
NASDAQ |
Jun 18, 13:17
INmune Bio Cash from Operations (TTM): -18.32M for March 31, 2024
Cash from Operations (TTM) Chart
Historical Cash from Operations (TTM) Data
Date | Value |
---|---|
March 31, 2024 | -18.32M |
December 31, 2023 | -11.98M |
September 30, 2023 | -14.27M |
June 30, 2023 | -13.38M |
March 31, 2023 | -14.96M |
December 31, 2022 | -22.69M |
September 30, 2022 | -26.77M |
June 30, 2022 | -31.33M |
March 31, 2022 | -32.28M |
December 31, 2021 | -28.50M |
September 30, 2021 | -21.12M |
Date | Value |
---|---|
June 30, 2021 | -16.89M |
March 31, 2021 | -13.00M |
December 31, 2020 | -8.943M |
September 30, 2020 | -6.984M |
June 30, 2020 | -5.232M |
March 31, 2020 | -5.032M |
December 31, 2019 | -5.385M |
September 30, 2019 | -5.414M |
June 30, 2019 | -3.918M |
March 31, 2019 | -3.118M |
December 31, 2018 | -2.059M |
Cash From Operations Definition
Cash flow from operations is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall operating activities of the company. A few examples of operating activities include change in receivables, change in inventories, and changes in current assets.
Cash from Operations (TTM) Range, Past 5 Years
-32.28M
Minimum
Mar 2022
-3.918M
Maximum
Jun 2019
-15.32M
Average
-13.83M
Median
Cash from Operations (TTM) Benchmarks
AVITA Medical Inc | -49.80M |
Dare Bioscience Inc | -29.55M |
Zevra Therapeutics Inc | -45.66M |
Xeris Biopharma Holdings Inc | -41.19M |
Kodiak Sciences Inc | -146.56M |